Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ATF4 | P18848 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717121 | 0.86 | NQO1 (0.47) | APPCYP1A2CYP2C9CYP2C19 | |
| 2-(4-Chlorphenoxy)-Ethanol SCHEMBL77500 | 0.80 | ALDH1A1 (0.60) | RAB9AMAOBNPSR1CYP1A2CYP2C19 | |
| SCHEMBL4383977 | 0.78 | DRD4 (0.52) | RAB9AHPGDNPSR1 | |
| 2-(4-Chlorphenoxy)-Ethanol SCHEMBL11264357 | 0.78 | ALDH1A1 (0.58) | RAB9AMAOBCYP1A2CYP2C19NPC1 | |
| SCHEMBL1345118 | 0.78 | MAOB (0.57) | RAB9AMAOBAPPNPSR1NPC1 | |
| SCHEMBL14513472 | 0.78 | ALDH1A1 (0.44) | RAB9AMAPTCYP2C9NPC1 | |
| SCHEMBL13481058 | 0.78 | LTA4H (0.50) | — | |
| SCHEMBL1003652 | 0.78 | MAOB (0.50) | RAB9AMAOBAPPNR4A2MAOA | |
| SCHEMBL11442484 | 0.77 | ALDH3A1 (0.53) | — | |
| SCHEMBL152253 | 0.76 | MAOB (0.48) | RAB9AMAOBAPPNR4A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0194984-A1 | Derivatives of imidazole, their preparation and utilisation, and pharmaceutical compositions containing these derivatives | CONTINENTAL PHARMA, INC. (BE) | 1986-09-17 | — | — | EP | claimed |
| WO-2021009209-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | Oncoarendi Therapeutics S.A. (PL) | 2021-01-21 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0194984-A1 | Derivatives of imidazole, their preparation and utilisation, and pharmaceutical compositions containing these derivatives | CONTINENTAL PHARMA, INC. (BE) | 1986-09-17 | — | — | EP | disclosed |
| US-4231781-A | Halophenoxy-alkoxy phosphonates and thiophosphonates | GAF CORPORATION (US) | 1980-11-04 | — | — | US | disclosed |
| US-4203757-A | Halophenoxyalkoxy phosphorous-containing sulfides | GAF CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-4148625-A | Tetrahydroisophthalimide compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | RAB9A 3153/4885MAPT 4299/4885POLB 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.